Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Partner
Lundbeckfond Ventures - Copenhagen, Denmark
Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY
Manager, Strategic Forecasting & Analytics Job
Celgene Corporation - Basking Ridge, NJ, US
Clinical Research Coordinator
Lovelace Respiratory Research Institute - Albuquerque, NM
Scientist/Sr. Scientist, Bio-analytical Chemistry
Dicerna Pharmaceuticals, Inc. - Watertown, MA

More Jobs >>

Events

New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA
CHI's Summit for Clinical Ops Executives (Scope)
February 7-9 — Miami
Life Science in the Cloud
Nov 16, 2011 — Cambridge, MA
Pharmacovigilance and Risk Management Strategies 2012
January 22-25, 2012 — Arlington, Virginia

More Events >>

Related Tags >> Immunovaccine Preflucel Johns Hopkins Transgene

Selecta Biosciences News

Most Popular Selecta Biosciences Story

Selecta gets a new CEO, $3M for nicotine vax program

August 18, 2010 — 1:20pm ET | By John Carroll

Selecta Biosciences has turned to a veteran of the pharma world to lead it through the startup phase. Werner Cautreels, who helmed Solvay Pharmaceuticals through its $6.6 billion sale to Abbott in Read more...

Selecta Biosciences Press Releases

Selecta Announces $47.25 Million Financing to Broaden R&D Capabilities and Accelerate Pipeline of Vaccines and Immunotherapies
Selecta Wins SAIC Subcontract to Develop Synthetic Nanoparticle Malaria Vaccine
Selecta Biosciences Appoints Peter Keller as Vice President of Business Development and Alliance Management
The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes
Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company's First CEO

Latest Headlines

Selecta gets a new CEO, $3M for nicotine vax program
August 18, 2010

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK